Elderly patients with acute myeloid leukaemia frequently cannot undergo intensive chemotherapy due to comorbidities. We report a retrospective case series of elderly patients with AML treated with low dose cytarabine induction. Eleven patients with at least 25% of bone marrow blasts expressing c-kit received Imatinib post-induction therapy, 7 patients entered as controls. Haematologic responses were only slightly better in the Imatinib cohort. No correlation of the response to Imatinib with c-kit expression was noted. Partly due to two early deaths in the control cohort, survival was longer in the Imatinib cohort. Imatinib post-induction therapy after cytarabine induction is feasible in elderly patients with AML not eligible for standard induction but responders to Imatinib have only limited benefit from this low-toxic therapy while no predictive response markers could be found.
INTRODUCTION
The outcome and survival of patients with acute myeloid leukaemia (AML) depends among other factors on the age of patients at the onset of the disease. 5-year overall survival rates of patients aged 55 years and older have slightly improved from 6% to 15% to about 10% and 25% as demonstrated in a review by the Eastern Cooperative Oncology Group (ECOG) on the outcome of more than 1400 patients with AML. [1] [2] [3] In contrast, the 5-year overall survival rate for patients younger than 60 years is approximately 40%. 4 A comparison of patients of all adult ages treated in multicenter trials revealed that older age is consistently associated with poorer complete remission rates and a shorter overall survival. 5 Thus, most patients with AML die of their disease as the median age of patients with AML at diagnosis is approximately 65 to 70 years. 6, 7 The outcome of patients with AML furthermore highly depends on characteristics of the disease as the cytogenetic karyotype, molecular findings, secondary vs. primary disease, response to induction therapy and the intensity of post-remission therapy. 8 In the population of elderly patients an accumulation of bad risk factors is found and intensity of induction therapy is often limited due to age-related morbidity. Treatment related side effects and infectious complications are generally more severe and thereby limit therapeutic possibilities in induction therapy or post-remission therapy.
Alternative approaches are warranted for elderly patients who are not eligible for standard induction therapy due to underlying morbidities or patient´s decision. These therapies might include antibodybased therapies, inhibition of angiogenesis or inhibition of intracellular signals that promote proliferation and/or block differentiation. [9] [10] [11] [12] . AML subtype M2 -associated with t(8;21) -and AML M4Eo -associated with inv (16) -so called core binding factor AMLs, have a high incidence of expression of early stem cell markers including kit, a receptor tyrosine kinase for the ligand stem cell factor (SCF) [13] [14] [15] and a relevant proportion of these patients harbour a mutated c-kit 16 with probably activating mutations. 17 c-kit is expressed with other subtypes of AML in up to 70% blasts and in vitro SCF leads to an increased proliferation of AML blasts. [18] [19] [20] The first specifically targeted small molecule tyrosine kinase inhibitor Imatinib mesylate (STI571, GleevecTM, GlivecTM) has had a major impact as single agent on the treatment of chronic myelogenous leukaemia (CML) 21 and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). 22 It is not only a potent inhibitor of all enzymes containing the Abl kinase domain including cAbl, but also the Abl related Arg, Kit and PDGFRs. 23 A study by Kindler et al 24 with Imatinib as sole therapy in patients with AML reported haematologic responses in a proportion of patients with acceptable toxicities. Based on the preclinical observations and preliminary study results we decided to evaluate on a single case bases the efficacy and toxicity of Imatinib mesylate used as post-induction therapy after a relatively low intensity induction chemotherapy with single cytarabine in patients with AML or advanced myelodysplastic syndrome with need to cytoreductive treatment. Informed consent was obtained from all patients.
MATERIAL AND METHODS

Patients
All patients evaluated in this analysis were treated in the wards and outpatient department of a single centre and best supportive care was administered following standard procedures.
Eleven of these patients received an Imatinib postinduction therapy beginning with a daily dose of 400 mg on the first or second day after the last do-se of cytarabine was administered. All patients of this group accepted to receive this treatment after careful consideration of possible advantages and disadvantages based on scarce available data.
In this context, Imatinib post-induction treatment was offered only to patients with at least 25% of blast expressing c-kit. No selection was performed on the basis of AML subtype, cytogenetics or prior therapy. Patients with severe hepatic impairment were not offered treatment with Imatinib.
Determination of biological characteristics:
Patient bone marrow was evaluated cytologically, histologically, immuno-histochemically and by standardized FACS analysis (Becter-Coulter), metaphase cytogenetics and interphase FiSH.
c-kit expression data was evaluated by FACS after gating the relevant population. If no bone marrow was available for FACS analysis, c-kit expression was analysed by immunohistochemistry.
Data collection:
All data was collected from files of the department of Haemato-Oncology of the hospital of the University of Frankfurt and from files of co-operating haemato-oncologists. Beside general and demographic data we evaluated the health status and concomitant diseases of the patients, the type and subtype of AML, cytogenetics and c-kit expression, prior AML therapies, toxicities of our treatment, response to treatment by week four, outcome and subsequent therapies.
Statistical analysis: Statistical analysis is descriptive. T-, χ
2 -and log rank tests were calculated where appropriate. Differences were considered significant if a p value below 0.05 was found. All calculations were done using SPSS version 16.
RESULTS
We identified 18 patients in our files that fulfilled the above mentioned inclusion criteria for this retrospective analysis. Of these 11 patients were treated with Imatinib mesylate and seven patients served as control cohort. Demographic data is shown in Table 1 . No significant differences in demographic bases were observed. Median age of patients was 69 years (range 62 to 84 years) in the Imatinib and 71 years (range 63 to 76 years) in the control cohort. Slightly more male patients received Imatinib which was not significant. All patients had a reduced ECOG performance status between I-II and suffered from different pre-existing co-morbidities. Both groups received the same antibiotic, antimycotic and supportive therapy when clinically indicated.
The distribution of patients with primary or secondary AML, with MDS RAEB and with unfavourable cytogenetics was comparable between both groups (Table 2) .
A minority of patients (5 of 11 in the Imatinib and 2 of 7 in the control cohort, not significant) had received different chemotherapeutic regimens before receiving cytarabine monotherapy. These regimens ranged from oral hydroxyl urea to standard induction therapy with cytarabine, idarubicin and etoposide phosphate.
Patients in the Imatinib group tended to have a higher c-kit expression on blasts consistent with the decision to offer Imatinib post-induction therapy to patients with at least 25% of blast expressing c-kit (Table 2) . One patient (STI #2) in the Imatinib group without c-kit expression on blasts was given Imatinib due to the patient's wish. This patient responded temporarily to induction therapy but progressed after only 16 days of Imatinib and died shortly after.
Two patients (AC #3, AC #5) in the control cohort eligible for Imatinib treatment refused this kind of therapy due to fear of side effects.
There were no statistically significant differences between the two groups concerning leukocyte or peripheral blast count before the start of cytarabine chemotherapy (Table 2) . Furthermore, no difference was seen clinically (ECOG PS) or concerning infections. Elevation of C reactive protein (CRP) was infrequently seen in both cohorts.
The median total dose of cytarabine administered was 865 mg (200-975 mg) in the Imatinib and 871 mg (200-999 mg) in the control cohort. Median dose of Imatinib was 6000 mg (6000-16300 mg) and median duration of Imatinib treatment was 14 days (min. 6 to max. 153 days).
There were two early deaths in the control group. It is noteworthy that of these patients one suffered from infectious complications with a clinical response after anti-infectious treatment and showed a falling tendency of the elevated CRP. Still, this patient died on the fifth day of chemotherapeutic treatment after a fatal septic shock with multi-organ 133 UHOD Number: 2 Volume: 23 Year: 2013 failure. The other patient died on day four of the treatment from a cardiac arrest of unknown origin. Autopsy led to the diagnosis of septic shock. Two more patients in the control group died from septic complications within four weeks after the initiation of chemotherapeutic treatment.
Concerning overall survival there was a significant difference between the Imatinib treated and the control cohort (median 326 vs. 28 days, p= 0.009). As there were the described two early deaths in the control cohort the comparison of survival is biased and the clinical impact remains unclear.
Haematological responses were evaluated by week four and the remainder of the patients in the control cohort did worse than the Imatinib cohort as there were complete remissions without full hematologic recovery in the Imatinib cohort whereas there were none in the control cohort (Table 3) after the induction therapy with cytarabine. Responses of all qualities occurred independent of AML subtype or primary or secondary disease (data not shown). It is still noteworthy that about three quarters of the patients in the Imatinib cohort received further chemotherapy (e.g. a second cycle of cytarabine, more aggressive induction chemotherapies or other maintenance therapies) while only one third of the patients in the control cohort did.
There was minor hepatic toxicity in the Imatinib cohort as four patients were found to have a clinically not significant bilirubin elevation. Only one of these four patients developed a diminished liver synthesis and had to stop Imatinib. This patient suffered from a minor hepatic dysfunction as a result of prior anti-rheumatic treatment and developed the No correlation was seen for c-kit expression and response (r=-0.14) or response duration (r=-0.12) or response to treatment and Imatinib treatment duration (r=0.54) or Imatinib total dose (r=0.53).
same adverse reactions after a second onset of Imatinib treatment. No renal toxicity grade II or higher occurred.
Hematologic toxicities were commonly due to cytarabine treatment. Those patients with a complete remission -all in the Imatinib cohort -recovered neutrophil counts to over 500/μl between four to six weeks after the first day of cytarabine. Patients with blast reduction only did not recover peripheral blood counts but the neutrophil count of some patients in both cohorts did not fall below 500/μl after cytarabine treatment.
Transfusion frequencies were comparable in both cohorts.
15 of 18 patients -except one in the control and two in the Imatinib cohort -suffered from infections. In the control cohort two patients had fever of unknown origin (FUO). These patients had a nadir of neutrophil counts above 500/μl. There were four pneumonias in the Imatinib cohort, furthermore two patients with FUO and one patient (with a history of multiple myeloma) with FUO and a clinically suspected generalized Herpes zoster reactivation. As stated above two patients in the control cohort died within days after the initiation of chemotherapeutic treatment from septic complications and two more within four weeks.
No other grade 3/4 side effects were reported.
DISCUSSION
In this case series we present an evaluation of feasibility and toxicity of an Imatinib post-induction therapy after cytarabine induction chemotherapy in patients with AML who were not eligible for more intense therapy regimens. Within the limitations of a retrospective case series with small patient numbers and heterogenous clinical characteristics and treatment, we observed a limited response to Imatinib in some patients ( 25 who used low dose cytarabine and Imatinib as continuous combined therapy for 21 days every 28 days. As our induction therapy was slightly more intense, we observed more and better hematologic responses but comparable results of the post-induction therapy. This translates into a prolonged median survival of 10.6 months in our Imatinib cohort compared to our control cohort or to the above mentioned study. 25 Patients of the same age group that could be treated with intensive induction chemotherapy within a multicentre clinical trial achieved CR in 64% and the median remission duration was about 15 months. 26 The early deaths in our case series and other toxicities are comparable to those reported in other reports. Nevertheless, the survival of our control cohort is biased as all early deaths occurred in this group; therefore the comparison with our control cohort is not substantial in the end. Even considering the early deaths in the control cohort, there seems to be a difference between both cohorts with respect to response duration. Perhaps, patients with a partial or complete response to induction chemotherapy might benefit from Imatinib as a rather low-toxic post-induction therapy and thereby obtain the possibility to receive further anti-neoplastic therapy.
No correlation of treatment response to c-kit expression was found in our patients. High levels of ckit expression were found in patients with progressive disease as well as in patients with complete remission and prolonged response duration. Patients with a blast reduction were found to have a broad spectrum of c-kit expression. Furthermore, no correlation of c-kit expression with duration of response, Imatinib treatment duration or Imatinib total dose was observed. Therefore, the mechanisms of response to Imatinib in c-kit positive AML remain to be elucidated. It was recently reported that Imatinib has anti-proliferative activity in AML blasts with increased c-kit expression or mutated c-kit and t (8;21) . 27 However, none of our patients presented with these features.
